In the Cartitude 1 trial, the strongest predictor of long-term remission with Siltacel was a lower burden of disease (measured by bone marrow percentage and soluble BCMA levels), rather than the number of prior treatments. This implies using CAR-T therapy earlier in the disease course is more effective.

Real-world data confirms that the favorable safety profile of CAR T-cell therapies like Obicell holds true in broad clinical practice. This has been a crucial factor in expanding eligibility to older patients, with successful treatments now being administered to individuals in their 70s and 80s.

The hype around in-vivo CAR-T overlooks that it's a more complex form of gene therapy. It relies on the same delivery vectors (AAVs, LNPs) that have caused patient deaths and off-target effects like liver concentration in simpler gene therapies, suggesting a difficult path to success.

Surprisingly, patients with high-risk cytogenetics, a typically poor prognostic factor in multiple myeloma, were equally represented in both the long-term remission group and the group that progressed after Siltacel treatment. This suggests CAR-T therapy may overcome traditional risk stratification.

Developing CAR T-cell therapies for solid tumors is difficult because many tumor-associated antigens are also expressed on normal tissues. This creates a significant risk of "on-target, off-tumor" effects, causing severe toxicity. Mitigating this risk, for instance with engineered "kill switches," is as crucial as preserving the therapy's efficacy.

Experts now view a patient's response to bridging therapy as a key predictor of CAR T outcomes. A patient who fails to respond or progresses during bridging has a much higher risk of toxicity and poor efficacy and should be considered for alternative treatments.

With highly effective treatments like CAR-T and bispecifics moving into earlier lines of therapy for multiple myeloma, the clinical focus must evolve. While efficacy benchmarks have been met, the next advancement requires vigilant attention to safety, particularly infection risks and other side effects of new paradigms.

Contrary to typical findings where real-world data underperforms, liso-cel CAR T-cell therapy in CLL demonstrates significantly better outcomes in practice than in its approval trial (over 80% response rate vs. under 50%). This suggests that using the therapy earlier in healthier, less-refractory patients unlocks its true potential.

While in vivo CAR-T could eliminate complex manufacturing, it lacks the safety guardrails of ex vivo methods. Clinicians cannot monitor the effective dose, count viral integrations, or guarantee that only T cells are engineered, posing significant risks of uncontrolled off-target effects.